Literature DB >> 24449580

A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus.

Maureen McMahon1, Brian J Skaggs, Jennifer M Grossman, Lori Sahakian, John Fitzgerald, Weng Kee Wong, Elaine V Lourenco, Nagesh Ragavendra, Christina Charles-Schoeman, Alan Gorn, George A Karpouzas, Mihaela B Taylor, Karol E Watson, Michael H Weisman, Daniel J Wallace, Bevra H Hahn.   

Abstract

OBJECTIVE: An increased frequency of atherosclerosis (ATH) in systemic lupus erythematosus (SLE) is well-documented but not fully explained by the presence of traditional cardiac risk factors. Several nontraditional biomarkers, including proinflammatory high-density lipoprotein (piHDL) and leptin, have been individually associated with subclinical ATH in SLE. The aim of this study was to examine whether these and other biomarkers can be combined into a risk profile, the Predictors of Risk for Elevated Flares, Damage Progression, and Increased Cardiovascular Disease in Patients with SLE (PREDICTS), that could be used to better predict future progression of ATH.
METHODS: In total, 210 patients with SLE and 100 age-matched healthy control subjects (all women) participated in this prospective cohort study. The longitudinal presence of carotid plaque and intima-media thickness (IMT) were measured at baseline and followup (mean ± SD 29.6 ± 9.7 months).
RESULTS: At followup, carotid plaque was present in 29% of SLE patients. Factors significantly associated with plaque, determined using Salford Predictive Modeling and multivariate analysis, included age ≥48 years (odds ratio [OR] 4.1, P = 0.002), high piHDL function (OR 9.1, P < 0.001), leptin levels ≥34 ng/dl (OR 7.3, P = 0.001), plasma soluble TWEAK levels ≥373 pg/ml (OR 28.8, P = 0.004), and history of diabetes (OR 61.8, P < 0.001). Homocysteine levels ≥12 μmoles/liter were also a predictor. However, no single variable demonstrated an ideal combination of good negative predictive values (NPVs), positive predictive values (PPVs), sensitivity, and specificity. A high-risk PREDICTS profile was defined as ≥3 positive biomarkers or ≥1 positive biomarker plus a history of diabetes; for high-risk SLE patients, the PPV was 64%, NPV was 94%, sensitivity was 89%, and specificity was 79%. In multivariate analysis, SLE patients with the high-risk profile had 28-fold increased odds for the longitudinal presence of plaque (P < 0.001) and increased progression of IMT (P < 0.001).
CONCLUSION: A high-risk PREDICTS score confers 28-fold increased odds of the presence of any current, progressive, or acquired carotid plaque, both in patients with SLE and in control subjects, and is significantly associated with higher rates of IMT progression.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24449580      PMCID: PMC4106468          DOI: 10.1002/art.38204

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  49 in total

1.  Equivalence trials in SLE research: issues to consider.

Authors:  M Y Kim; J P Buyon; M Petri; M L Skovron; R E Shore
Journal:  Lupus       Date:  1999       Impact factor: 2.911

2.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  J M Esdaile; M Abrahamowicz; T Grodzicky; Y Li; C Panaritis; R du Berger; R Côte; S A Grover; P R Fortin; A E Clarke; J L Senécal
Journal:  Arthritis Rheum       Date:  2001-10

3.  Soluble TWEAK level: is it a marker for cardiovascular disease in long-term hemodialysis patients?

Authors:  Ozkan Gungor; Fatih Kircelli; Gulay Asci; Juan Jesus Carrero; Erhan Tatar; Meltem Sezis Demirci; Süreyya Süha Ozbek; Naim Ceylan; Huseyin Toz; Mehmet Ozkahya; Ercan Ok
Journal:  J Nephrol       Date:  2013 Jan-Feb       Impact factor: 3.902

4.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.

Authors: 
Journal:  JAMA       Date:  2002 Oct 23-30       Impact factor: 56.272

5.  A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids.

Authors:  M Navab; S Y Hama; G P Hough; G Subbanagounder; S T Reddy; A M Fogelman
Journal:  J Lipid Res       Date:  2001-08       Impact factor: 5.922

Review 6.  Role of leptin in blood pressure regulation and arterial hypertension.

Authors:  Jerzy Bełtowski
Journal:  J Hypertens       Date:  2006-05       Impact factor: 4.844

7.  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  Mary J Roman; Beth-Ann Shanker; Adrienne Davis; Michael D Lockshin; Lisa Sammaritano; Ronit Simantov; Mary K Crow; Joseph E Schwartz; Stephen A Paget; Richard B Devereux; Jane E Salmon
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

8.  Serum leptin levels in women with systemic lupus erythematosus.

Authors:  Araceli Garcia-Gonzalez; Laura Gonzalez-Lopez; Isela C Valera-Gonzalez; Ernesto G Cardona-Muñoz; Mario Salazar-Paramo; Manuel González-Ortiz; Esperanza Martínez-Abundis; Jorge I Gamez-Nava
Journal:  Rheumatol Int       Date:  2002-06-27       Impact factor: 2.631

9.  Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.

Authors:  Benjamin J Ansell; Mohamad Navab; Susan Hama; Naeimeh Kamranpour; Gregg Fonarow; Greg Hough; Shirin Rahmani; Rachel Mottahedeh; Ravi Dave; Srinivasa T Reddy; Alan M Fogelman
Journal:  Circulation       Date:  2003-11-24       Impact factor: 29.690

10.  The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis.

Authors:  Joseph F Polak; Moyses Szklo; Richard A Kronmal; Gregory L Burke; Steven Shea; Anna E H Zavodni; Daniel H O'Leary
Journal:  J Am Heart Assoc       Date:  2013-04-08       Impact factor: 5.501

View more
  37 in total

1.  Characteristics of immunogenic and tolerogenic dendritic cells within the arterial wall in atherosclerosis and in vitro.

Authors:  Zhengdong Fang; Qiong Deng; Hejie Hu; Xiaotian Wang; Xiaojie Sun; Xinbao Ge; Peishuang Wang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort.

Authors:  Paola A Zeña-Huancas; Haydee Iparraguirre-López; Rocío V Gamboa-Cárdenas; Cristina Reátegui-Sokolova; Francisco Zevallos-Miranda; Mariela Medina-Chinchon; Victor R Pimentel-Quiroz; Claudia Elera-Fitzcarrald; Omar Sarmiento-Velasquez; Jorge M Cucho-Venegas; José L Alfaro-Lozano; Zoila J Rodríguez-Bellido; César A Pastor-Asurza; Risto A Perich-Campos; Graciela S Alarcón; Manuel F Ugarte-Gil
Journal:  Clin Rheumatol       Date:  2018-12-12       Impact factor: 2.980

Review 3.  Pathogenesis and treatment of atherosclerosis in lupus.

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

4.  Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis.

Authors:  Michelle J Ormseth; Patricia G Yancey; Suguru Yamamoto; Annette M Oeser; Tebeb Gebretsadik; Ayumi Shintani; MacRae F Linton; Sergio Fazio; Sean S Davies; L Jackson Roberts; Kasey C Vickers; Paolo Raggi; Valentina Kon; C Michael Stein
Journal:  IJC Metab Endocr       Date:  2016-08-28

Review 5.  Leptin, cardiovascular diseases and type 2 diabetes mellitus.

Authors:  Niki Katsiki; Dimitri P Mikhailidis; Maciej Banach
Journal:  Acta Pharmacol Sin       Date:  2018-06-07       Impact factor: 6.150

6.  Antiphospholipid Antibodies and Heart Valve Disease in Systemic Lupus Erythematosus.

Authors:  Daniel Ruiz; Jim C Oates; Diane L Kamen
Journal:  Am J Med Sci       Date:  2017-07-20       Impact factor: 2.378

7.  Lipid profile among girls with systemic lupus erythematosus.

Authors:  Daniele Machado; Roseli O S Sarni; Thaís T O Abad; Simone G L Silva; Eugênia J B Khazaal; Sonia Hix; Milena S G Correia; Fabíola I Suano-Souza; Claudio A Len; Maria Teresa R A Terreri
Journal:  Rheumatol Int       Date:  2015-11-16       Impact factor: 2.631

8.  GlycA, a novel marker of inflammation, is elevated in systemic lupus erythematosus.

Authors:  C P Chung; M J Ormseth; M A Connelly; A Oeser; J F Solus; J D Otvos; P Raggi; C M Stein
Journal:  Lupus       Date:  2015-12-03       Impact factor: 2.911

Review 9.  Update on cardiovascular disease in lupus.

Authors:  Laura B Lewandowski; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

10.  The effects of exercise on lipid profile in systemic lupus erythematosus and healthy individuals: a randomized trial.

Authors:  Fabiana Braga Benatti; Renata Miossi; Marisa Passareli; Edna R Nakandakare; Luiz Perandini; Fernanda Rodrigues Lima; Hamilton Roschel; Eduardo Borba; Eloisa Bonfá; Bruno Gualano; Ana Lúcia de Sá Pinto
Journal:  Rheumatol Int       Date:  2014-06-28       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.